336 related articles for article (PubMed ID: 27000800)
1. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
Yeh JS; Sarpatwari A; Kesselheim AS
Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
[TBL] [Abstract][Full Text] [Related]
2. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
[TBL] [Abstract][Full Text] [Related]
4. Boxed warning inconsistencies between drug information resources and the prescribing information.
Cheng CM; Fu C; Guglielmo BJ; Auerbach AD
Am J Health Syst Pharm; 2011 Sep; 68(17):1626-31. PubMed ID: 21856808
[TBL] [Abstract][Full Text] [Related]
5. FDA boxed warnings: how to prescribe drugs safely.
O'Connor NR
Am Fam Physician; 2010 Feb; 81(3):298-303. PubMed ID: 20112888
[TBL] [Abstract][Full Text] [Related]
6. US Food and Drug Administration Black Box Warnings.
Smith RG
J Am Podiatr Med Assoc; 2020 Jan; 110(1):Article10. PubMed ID: 32073327
[TBL] [Abstract][Full Text] [Related]
7. New and incremental FDA black box warnings from 2008 to 2015.
Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS
Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916
[TBL] [Abstract][Full Text] [Related]
8. Impact of FDA Actions, DTCA, and Public Information on the Market for Pain Medication.
Bradford WD; Kleit AN
Health Econ; 2015 Jul; 24(7):859-75. PubMed ID: 25059655
[TBL] [Abstract][Full Text] [Related]
9. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.
Cook DM; Gurugubelli RK; Bero LA
Drug Saf; 2009; 32(11):1057-66. PubMed ID: 19810777
[TBL] [Abstract][Full Text] [Related]
10. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
[TBL] [Abstract][Full Text] [Related]
11. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility.
Matlock A; Allan N; Wills B; Kang C; Leikin JB
Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886
[TBL] [Abstract][Full Text] [Related]
12. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.
Cheng CM; Shin J; Guglielmo BJ
JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107
[No Abstract] [Full Text] [Related]
13. Differences between the United States and Japan in labels of oncological drugs.
Jayaputra K; Ono S
Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):143-151. PubMed ID: 27670850
[TBL] [Abstract][Full Text] [Related]
14. Bringing greater transparency to "black box" warnings.
Buckley NA; Rossi S
Clin Toxicol (Phila); 2011 Jul; 49(6):448-51. PubMed ID: 21824055
[TBL] [Abstract][Full Text] [Related]
15. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
Frank C; Himmelstein DU; Woolhandler S; Bor DH; Wolfe SM; Heymann O; Zallman L; Lasser KE
Health Aff (Millwood); 2014 Aug; 33(8):1453-9. PubMed ID: 25092848
[TBL] [Abstract][Full Text] [Related]
16. Summaries of Safety Labeling Changes Approved By FDA-Boxed Warnings Highlights July-September 2015.
Am J Health Syst Pharm; 2015 Dec; 72(23):e60-8. PubMed ID: 26581940
[No Abstract] [Full Text] [Related]
17. Summaries of Safety Labeling Changes Approved By FDA--Boxed Warnings Highlights July--September 2015.
Am J Health Syst Pharm; 2015 Dec; 72(23):2008. PubMed ID: 26581924
[No Abstract] [Full Text] [Related]
18. The Value of the Black Box Warning in Dermatology.
Winterfield L; Vleugels RA; Park KK
J Drugs Dermatol; 2015 Jul; 14(7):660-6. PubMed ID: 26151780
[TBL] [Abstract][Full Text] [Related]
19. Prescribing Antipsychotic Medications to Patients With Dementia: Boxed Warnings and Mitigation of Legal Liability.
Rose RV; Kass JS
Continuum (Minneap Minn); 2019 Feb; 25(1):254-259. PubMed ID: 30707196
[TBL] [Abstract][Full Text] [Related]
20. Summaries of safety labeling changes approved by FDA-boxed warnings highlights January-March 2016.
Am J Health Syst Pharm; 2016 Jun; 73(11):e375-7. PubMed ID: 27208062
[No Abstract] [Full Text] [Related]
[Next] [New Search]
